Find The Best Stocks With Perfect Trade Setups In Minutes A Day

Stop wasting time looking for the right stocks.  Free training on how to find perfect stock trades that can move 300-1,500%.  Learn the # 1 key to successful stock investing and how to find success even If the market is crashing, rebounding… or just going sideways.

Do Not Delay - Click Here Now


Why Morgan Stanley Just Issued A Double Upgrade On 1 Biotech Stock

One analyst says this stock could gain nearly 30% in the near-term.

Morgan Stanley issued a rare double upgrade this week for Biogen (NASDAQ: BIIB).

If you're a stock investor who wants to retire early, check out this free training and learn how!  Click Here

Analyst Matthew Harrison raised his rating on the stock from Underweight to Overweight, and boosted his price target for Biogen shares to $357 – nearly 30% higher than the price as of this writing.

“While BIIB remains a high-risk/high-reward stock, we think now is the right time to take the risk,” Harrison wrote in a note to clients. 

Biogen has had a big month. 

Early in July, the biotech submitted its Alzheimer’s disease drug, aducanumab, to the Food and Drug Administration for approval. Biogen canceled a pivotal trial for the drug last year after it failed a so-called futility analysis but if approved, aducanumab would be the first medicine available to slow the memory-wasting disease. 

Harrison argues there’s a 50% chance the FDA will approve the drug—a final decision is expected by March 2021—while the stock reflects just a 25% chance of approval.

The submission of aducanumab “finally begins the big journey of what will be a hotly debated FDA review,” said Jefferies analyst Michael Yee, who also sees a “50/50 or better” chance of approval for the drug and argues an approval would send Biogen shares to $500 or higher.

Then last week, Biogen delivered an earnings beat, posting adjusted earnings per share of $10.26 on revenue of $3.68 billion, compared to estimates for earnings per share of $8.02 on revenue of $3.43 billion. 

Biogen also upped its full-year guidance, estimating GAAP diluted earnings per share to come in between $32 and $34, above the previous estimated range of between $29.50 and $31.50.

Even with these big catalysts, Harrison warns the stock could fall in the near term, though that fall could present a good buying opportunity for the stock.

Biogen’s multiple sclerosis drug Tecfidera is expected to face generic competition after a federal court invalidated the company’s patent last month.

“In the near-term, we believe BIIB is likely to face 10%+ in downside pressure due to multiple at-risk generic launches for multiple sclerosis (MS) drug Tecfidera,” Harrison said in the note. “While we expect generic Tecfidera competitors in the near-term, we believe investors should start to average into a long position in BIIB now despite that downside risk.”

“We expect investors to quickly look past the Tecfidera downside and state to price in higher odds of success for aducanumab, Biogen’s investigational drug which is the first potential disease-modifying therapy for Alzheimer’s disease,” Harrison added.

By the way, if you liked this article, you'll LOVE this Meaty free training I just published on the top 3 questions and challenges every investor faces AND how to overcome them. It's titled "10k into $2.4 Million in 18 months" and you can grab it for free here

There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses. Information provided by the Company is not investment advice. The Company is not a registered investment adviser, stock broker, or brokerage. You agree that the Company does not represent, warrant, or take responsibility that any account will or is likely to achieve profit or losses similar to those shown. Examples published by the Company are selected for illustrative purposes only. They are not typical and do not represent the typical results of all stocks within the Companys software or its individual scans and searches. No independent party has audited any hypothetical performance contained at this Web site, nor has any independent party undertaken to confirm that they reflect the trading method under the assumptions or conditions specified.

FREE TRADING WEBINAR - TRADERSPRO PRESENTS: Starting With Only $10,000 Retire With $2.4 Million? Click Here Now

Join Us Now